相关实验视频
Updated: May 1, 2026

05:37
Intravitreous Injection for Establishing Ocular Diseases Model
Published on: October 1, 2007
36.6K
内无注入器装置 (IPLID):一种创新的内注入器装置
Juan B Yepez1, Felipe A Murati2, Michele Petitto3
1Vitreoretinal Surgery Department, Clinica de Ojos, Maracaibo, Venezuela.
Clinical ophthalmology (Auckland, N.Z.)
|February 19, 2025
概括
新型静脉注射器无注射器装置 (IPLID) 为静脉注射提供了一种舒适安全的方法. 与传统方法相比,大多数患者的疼痛程度较小或类似,外科医生报告说使用方便.
科学领域:
- 眼科医生 眼科 眼科
- 医疗器械 医疗器械
- 视网膜疾病 视网膜疾病
背景情况:
- 静脉内注射是各种视网膜疾病的常见治疗方法.
- 传统的注射装置可能会给医疗保健专业人员带来人体工程学方面的挑战.
研究的目的:
- 评估早期的临床经验,使用一种新型的静脉内无注射器装置 (IPLID).
- 评估患者报告的疼痛和外科医生对内内注射IPLID的反.
主要方法:
- 一项涉及300只眼睛 (300名患者) 的视网膜疾病的研究,包括糖尿病性黄斑,湿性AMD和新血管玻璃眼.
- 患者使用IPLID接受了静脉内注射,并将他们的疼痛经历与之前的常规注射进行了比较.
- 外科医生完成了关于设备安全性,舒适性和手术持续时间的调查.
主要成果:
- 与传统注射相比,超过51%的患者报告IPLID的疼痛减少.
- 使用IPLID进行的注射中有86.67%对外科医生来说是舒适的.
- 在IPLID注射期间或之后没有报告任何不良事件.
结论:
- 静脉内无注射器装置 (IPLID) 是用于静脉内注射的安全有效工具.
- IPLID可以提供人体工程学的优势,可能减少医疗保健人员的肌肉骨应变.
相关概念视频
Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices
208
Parenteral drug delivery systems play a crucial role in modern therapeutics by enabling the direct administration of drugs into the systemic circulation, bypassing the gastrointestinal tract. These systems are particularly valuable for poorly absorbed oral medications that are unstable in the digestive environment or require rapid onset or sustained therapeutic levels. Delivery is achieved through intravenous, intramuscular, or subcutaneous routes, each selected based on the drug's properties...
208
Ophthalmic Drug Delivery Systems
283
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
283

